PI3
peptidase inhibitor 3, skin-derived
PI3; peptidase inhibitor 3, skin-derived; ESI; WAP3; SKALP; WFDC14; cementoin; elafin; PI-3; trappin-2; pre-elafin; protease inhibitor WAP3; elastase-specific inhibitor; skin-derived antileukoproteinase; WAP four-disulfide core domain 14; WAP four-disulfide core domain protein 14; protease inhibitor 3, skin-derived (SKALP);
PKP1
plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)
B6P; PKP1; MGC138829; Plakophilin 1;
DPCD
deleted in primary ciliary dyskinesia homolog (mouse)
DPCD; deleted in primary ciliary dyskinesia homolog (mouse); protein DPCD; DKFZP566F084; RP11 529I10.4; Deleted in a mouse model of primary ciliary dyskinesia; DPCD protein; OTTHUMP00000020329; OTTHUMP00000020331; RP11-529I10.4;
PNKD
paroxysmal nonkinesigenic dyskinesia
PNKD; paroxysmal nonkinesigenic dyskinesia; paroxysmal nonkinesiogenic dyskinesia; probable hydrolase PNKD; BRP17; DKFZp564N1362; DYT8; FKSG19; FPD1; KIAA1184; KIPP1184; MGC31943; MR 1; myofibrillogenesis regulator 1; PDC; PKND1; TAHCCP2; brain protein 17; trans-activated by hepatitis C virus core protein 2; MR1; MR-1;
D15Ertd621e
DNA segment, Chr 15, ERATO Doi 621, expressed
SKIN; Fam91a1; AV220772; BC033609; mKIAA0493;
Non-Animal Skin Sensitization Testing Services
Allergic Contact Dermatitis (ACD) is a complex disease, and it is estimated that 15-20% of the general population suffers from contact allergy, with increasing prevalence. Assessment of skin sensitization potential is therefore an important component of the safety evaluation process for cosmetics an...
